BR112017017812A2 - materiais e métodos para tratamento de hemoglobinopatias - Google Patents
materiais e métodos para tratamento de hemoglobinopatiasInfo
- Publication number
- BR112017017812A2 BR112017017812A2 BR112017017812A BR112017017812A BR112017017812A2 BR 112017017812 A2 BR112017017812 A2 BR 112017017812A2 BR 112017017812 A BR112017017812 A BR 112017017812A BR 112017017812 A BR112017017812 A BR 112017017812A BR 112017017812 A2 BR112017017812 A2 BR 112017017812A2
- Authority
- BR
- Brazil
- Prior art keywords
- methods
- hemoglobinopathies
- materials
- cells
- hbf
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 4
- 208000034737 hemoglobinopathy Diseases 0.000 title abstract 3
- 208000018337 inherited hemoglobinopathy Diseases 0.000 title abstract 3
- 210000000130 stem cell Anatomy 0.000 abstract 2
- 108010044495 Fetal Hemoglobin Proteins 0.000 abstract 1
- 206010043391 Thalassaemia beta Diseases 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 238000010362 genome editing Methods 0.000 abstract 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 abstract 1
- 208000007056 sickle cell anemia Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
- A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/41—Porphyrin- or corrin-ring-containing peptides
- A61K38/42—Haemoglobins; Myoglobins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/102—Mutagenizing nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0696—Artificially induced pluripotent stem cells, e.g. iPS
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/10—Applications; Uses in screening processes
- C12N2320/11—Applications; Uses in screening processes for the determination of target sites, i.e. of active nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/70—Enzymes
- C12N2501/73—Hydrolases (EC 3.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Abstract
a presente invenção refere-se a materiais e métodos para tratamento de hemoglobinopatias. mais especificamente, o pedido refere-se a métodos para produzir células progenitoras que são geneticamente modificadas via edição de genoma para aumentar a produção de hemoglobina fetal (hbf), bem como células progenitoras modificadas (incluindo, por exemplo, células tronco hematopoiéticas cd34+) que produzem níveis aumentados de hbf, e métodos de utilização de tais células para tratamento de hemoglobinopatias tais como anemia de célula falciforme e ß-talassemia.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562119754P | 2015-02-23 | 2015-02-23 | |
PCT/IB2016/000282 WO2016135558A2 (en) | 2015-02-23 | 2016-02-23 | Materials and methods for treatment of hemoglobinopathies |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112017017812A2 true BR112017017812A2 (pt) | 2018-04-10 |
Family
ID=55795007
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112017017812A BR112017017812A2 (pt) | 2015-02-23 | 2016-02-23 | materiais e métodos para tratamento de hemoglobinopatias |
BR112017017810A BR112017017810A2 (pt) | 2015-02-23 | 2016-02-23 | materiais e métodos para tratamento de hemoglobinopatias |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112017017810A BR112017017810A2 (pt) | 2015-02-23 | 2016-02-23 | materiais e métodos para tratamento de hemoglobinopatias |
Country Status (8)
Country | Link |
---|---|
US (3) | US20180030438A1 (pt) |
EP (2) | EP3262172A2 (pt) |
CN (2) | CN107532168A (pt) |
AU (2) | AU2016225178B2 (pt) |
BR (2) | BR112017017812A2 (pt) |
CA (2) | CA2977447A1 (pt) |
SG (2) | SG11201706767RA (pt) |
WO (2) | WO2016135557A2 (pt) |
Families Citing this family (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013066438A2 (en) | 2011-07-22 | 2013-05-10 | President And Fellows Of Harvard College | Evaluation and improvement of nuclease cleavage specificity |
BR112015026197B1 (pt) | 2013-04-16 | 2022-12-06 | Regeneron Pharmaceuticals, Inc | Método para modificação marcada de um lócus genômico de interesse em uma célula de rato pluripotente |
US9163284B2 (en) | 2013-08-09 | 2015-10-20 | President And Fellows Of Harvard College | Methods for identifying a target site of a Cas9 nuclease |
US9359599B2 (en) | 2013-08-22 | 2016-06-07 | President And Fellows Of Harvard College | Engineered transcription activator-like effector (TALE) domains and uses thereof |
US9322037B2 (en) | 2013-09-06 | 2016-04-26 | President And Fellows Of Harvard College | Cas9-FokI fusion proteins and uses thereof |
US9526784B2 (en) | 2013-09-06 | 2016-12-27 | President And Fellows Of Harvard College | Delivery system for functional nucleases |
US9228207B2 (en) | 2013-09-06 | 2016-01-05 | President And Fellows Of Harvard College | Switchable gRNAs comprising aptamers |
RU2685914C1 (ru) | 2013-12-11 | 2019-04-23 | Регенерон Фармасьютикалс, Инк. | Способы и композиции для направленной модификации генома |
US20150165054A1 (en) | 2013-12-12 | 2015-06-18 | President And Fellows Of Harvard College | Methods for correcting caspase-9 point mutations |
EP3122880B1 (en) | 2014-03-26 | 2021-05-05 | Editas Medicine, Inc. | Crispr/cas-related methods and compositions for treating sickle cell disease |
US10077453B2 (en) | 2014-07-30 | 2018-09-18 | President And Fellows Of Harvard College | CAS9 proteins including ligand-dependent inteins |
LT3221457T (lt) | 2014-11-21 | 2019-06-10 | Regeneron Pharmaceuticals, Inc. | Nukreipiančios genetinės modifikacijos būdai ir kompozicijos, naudojant suporuotas kreipiančiąsias rnr sekas |
EP3262172A2 (en) | 2015-02-23 | 2018-01-03 | Crispr Therapeutics AG | Materials and methods for treatment of hemoglobinopathies |
JP7030522B2 (ja) | 2015-05-11 | 2022-03-07 | エディタス・メディシン、インコーポレイテッド | 幹細胞における遺伝子編集のための最適化crispr/cas9システムおよび方法 |
WO2016201047A1 (en) | 2015-06-09 | 2016-12-15 | Editas Medicine, Inc. | Crispr/cas-related methods and compositions for improving transplantation |
WO2017053729A1 (en) | 2015-09-25 | 2017-03-30 | The Board Of Trustees Of The Leland Stanford Junior University | Nuclease-mediated genome editing of primary cells and enrichment thereof |
EP3365357B1 (en) | 2015-10-23 | 2024-02-14 | President and Fellows of Harvard College | Evolved cas9 proteins for gene editing |
WO2017077394A2 (en) * | 2015-11-04 | 2017-05-11 | Crispr Therapeutics Ag | Materials and methods for treatment of hemoglobinopathies |
EP3430142A1 (en) * | 2016-03-14 | 2019-01-23 | Editas Medicine, Inc. | Crispr/cas-related methods and compositions for treating beta hemoglobinopathies |
AU2017306676B2 (en) | 2016-08-03 | 2024-02-22 | President And Fellows Of Harvard College | Adenosine nucleobase editors and uses thereof |
AU2017308889B2 (en) | 2016-08-09 | 2023-11-09 | President And Fellows Of Harvard College | Programmable Cas9-recombinase fusion proteins and uses thereof |
US11542509B2 (en) | 2016-08-24 | 2023-01-03 | President And Fellows Of Harvard College | Incorporation of unnatural amino acids into proteins using base editing |
SG11201903089RA (en) | 2016-10-14 | 2019-05-30 | Harvard College | Aav delivery of nucleobase editors |
WO2018119359A1 (en) | 2016-12-23 | 2018-06-28 | President And Fellows Of Harvard College | Editing of ccr5 receptor gene to protect against hiv infection |
EP3573618B1 (en) * | 2017-01-30 | 2023-08-16 | The Children's Hospital of Philadelphia | Compositions and methods for hemoglobin production |
TW201839136A (zh) * | 2017-02-06 | 2018-11-01 | 瑞士商諾華公司 | 治療血色素異常症之組合物及方法 |
WO2018165504A1 (en) | 2017-03-09 | 2018-09-13 | President And Fellows Of Harvard College | Suppression of pain by gene editing |
US11542496B2 (en) | 2017-03-10 | 2023-01-03 | President And Fellows Of Harvard College | Cytosine to guanine base editor |
EP3596217A1 (en) | 2017-03-14 | 2020-01-22 | Editas Medicine, Inc. | Systems and methods for the treatment of hemoglobinopathies |
IL306092A (en) | 2017-03-23 | 2023-11-01 | Harvard College | Nucleic base editors that include nucleic acid programmable DNA binding proteins |
EP3622070A2 (en) | 2017-05-10 | 2020-03-18 | Editas Medicine, Inc. | Crispr/rna-guided nuclease systems and methods |
WO2018209320A1 (en) | 2017-05-12 | 2018-11-15 | President And Fellows Of Harvard College | Aptazyme-embedded guide rnas for use with crispr-cas9 in genome editing and transcriptional activation |
WO2019003193A1 (en) * | 2017-06-30 | 2019-01-03 | Novartis Ag | METHODS FOR TREATING DISEASES USING GENE EDITING SYSTEMS |
WO2019014564A1 (en) | 2017-07-14 | 2019-01-17 | Editas Medicine, Inc. | SYSTEMS AND METHODS OF TARGETED INTEGRATION AND GENOME EDITING AND DETECTION THEREOF WITH INTEGRATED PRIMING SITES |
JP2020534795A (ja) | 2017-07-28 | 2020-12-03 | プレジデント アンド フェローズ オブ ハーバード カレッジ | ファージによって支援される連続的進化(pace)を用いて塩基編集因子を進化させるための方法および組成物 |
WO2019139645A2 (en) | 2017-08-30 | 2019-07-18 | President And Fellows Of Harvard College | High efficiency base editors comprising gam |
US11795443B2 (en) | 2017-10-16 | 2023-10-24 | The Broad Institute, Inc. | Uses of adenosine base editors |
MA50849A (fr) * | 2017-10-26 | 2020-09-02 | Vertex Pharma | Substances et procédés pour le traitement d'hémoglobinopathies |
CN108103027B (zh) * | 2018-02-02 | 2021-12-24 | 中国医学科学院血液病医院(血液学研究所) | 高效率血细胞重编程同时实现基因编辑的方法 |
EP3749768A1 (en) | 2018-02-05 | 2020-12-16 | Vertex Pharmaceuticals Incorporated | Materials and methods for treatment of hemoglobinopathies |
AU2019230210A1 (en) * | 2018-03-07 | 2020-10-01 | Editas Medicine, Inc. | Systems and methods for the treatment of hemoglobinopathies |
AU2019234922A1 (en) * | 2018-03-14 | 2020-10-22 | Editas Medicine, Inc. | Systems and methods for the treatment of hemoglobinopathies |
EP3802826A1 (en) * | 2018-05-24 | 2021-04-14 | CRISPR Therapeutics AG | Methods and compositions for efficient gene deletion |
CN110863041A (zh) * | 2018-08-27 | 2020-03-06 | 深圳华大生命科学研究院 | 一种与地中海贫血相关的突变基因及其检测试剂和应用 |
WO2020092611A1 (en) * | 2018-10-30 | 2020-05-07 | Casebia Therapeutics Limited Liability Partnership | Compositions and methods for nhej-mediated genome editing |
CN113727660A (zh) * | 2019-02-26 | 2021-11-30 | 佩克阿西斯特公司 | 用于经皮气动心脏辅助的设备、***和方法 |
JP2022526908A (ja) | 2019-03-19 | 2022-05-27 | ザ ブロード インスティテュート,インコーポレーテッド | 編集ヌクレオチド配列を編集するための方法および組成物 |
CN111939271A (zh) * | 2019-04-30 | 2020-11-17 | 博雅辑因(北京)生物科技有限公司 | 一种血红蛋白病治疗有效性预测方法 |
CA3138029A1 (en) * | 2019-04-30 | 2020-11-05 | Edigene Inc. | Method for predicting effectiveness of treatment of hemoglobinopathy |
US20230022146A1 (en) | 2019-06-17 | 2023-01-26 | Vertex Pharmaceuticals Incorporated | Compositions and methods for editing beta-globin for treatment of hemaglobinopathies |
CN110699381A (zh) * | 2019-09-17 | 2020-01-17 | 合肥瑞灵生物科技有限公司 | 地中海贫血病基因治疗载体构建方法及其用途 |
AU2021267940A1 (en) | 2020-05-08 | 2022-12-08 | President And Fellows Of Harvard College | Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence |
WO2022147759A1 (en) * | 2021-01-08 | 2022-07-14 | Susheng Biotech (Hainan) Co., Ltd. | Grna molecule targeting intron i or intron ii of hbb gene, synthetic method thereof, and method to correct types of hbb gene mutations |
WO2023028469A2 (en) * | 2021-08-23 | 2023-03-02 | The Board Of Trustees Of The Leland Stanford Junior University | Targeted integration at beta-globin locus in human hematopoietic stem and progenitor cells |
CN113564248A (zh) * | 2021-09-26 | 2021-10-29 | 北京贝瑞和康生物技术有限公司 | 同时检测hba1/2、hbb和hbd基因位点多种突变的方法和试剂盒 |
WO2024073751A1 (en) | 2022-09-29 | 2024-04-04 | Vor Biopharma Inc. | Methods and compositions for gene modification and enrichment |
Family Cites Families (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR901228A (fr) | 1943-01-16 | 1945-07-20 | Deutsche Edelstahlwerke Ag | Système d'aimant à entrefer annulaire |
US5173414A (en) | 1990-10-30 | 1992-12-22 | Applied Immune Sciences, Inc. | Production of recombinant adeno-associated virus vectors |
DE69433592T2 (de) | 1993-11-09 | 2005-02-10 | Targeted Genetics Corp., Seattle | Die erzielung hoher titer des rekombinanten aav-vektors |
EP0728214B1 (en) | 1993-11-09 | 2004-07-28 | Medical College Of Ohio | Stable cell lines capable of expressing the adeno-associated virus replication gene |
US5658785A (en) | 1994-06-06 | 1997-08-19 | Children's Hospital, Inc. | Adeno-associated virus materials and methods |
US5856152A (en) | 1994-10-28 | 1999-01-05 | The Trustees Of The University Of Pennsylvania | Hybrid adenovirus-AAV vector and methods of use therefor |
WO1996017947A1 (en) | 1994-12-06 | 1996-06-13 | Targeted Genetics Corporation | Packaging cell lines for generation of high titers of recombinant aav vectors |
FR2737730B1 (fr) | 1995-08-10 | 1997-09-05 | Pasteur Merieux Serums Vacc | Procede de purification de virus par chromatographie |
CA2625279A1 (en) | 1995-08-30 | 1997-03-06 | Genzyme Corporation | Chromatographic purification of adenovirus and aav |
JPH11514853A (ja) | 1995-09-08 | 1999-12-21 | ジエンザイム コーポレイション | 遺伝子治療のための改良されたaavベクター |
US5910434A (en) | 1995-12-15 | 1999-06-08 | Systemix, Inc. | Method for obtaining retroviral packaging cell lines producing high transducing efficiency retroviral supernatant |
PT1944362E (pt) | 1997-09-05 | 2016-01-27 | Genzyme Corp | Métodos de produção de preparações de alto título de vetores aav recombinantes desprovidos de adjuvantes |
US6258595B1 (en) | 1999-03-18 | 2001-07-10 | The Trustees Of The University Of Pennsylvania | Compositions and methods for helper-free production of recombinant adeno-associated viruses |
US7056502B2 (en) | 2000-04-28 | 2006-06-06 | The Trustees Of The University Of Pennsylvania | Recombinant aav vectors with AAV5 capsids and AAV5 vectors pseudotyped in heterologous capsids |
MXPA03003690A (es) | 2000-10-27 | 2004-05-05 | Chiron Spa | Acidos nucleicos y proteinas de los grupos a y b de estreptococos. |
EP3208339B1 (en) | 2008-09-15 | 2019-05-01 | The Children's Medical Center Corporation | Modulation of bcl11a for treatment of hemoglobinopathies |
EP3272356A1 (en) * | 2012-02-24 | 2018-01-24 | Fred Hutchinson Cancer Research Center | Compositions and methods for the treatment of hemoglobinopathies |
DE102012007232B4 (de) | 2012-04-07 | 2014-03-13 | Susanne Weller | Verfahren zur Herstellung von rotierenden elektrischen Maschinen |
LT3401400T (lt) | 2012-05-25 | 2019-06-10 | The Regents Of The University Of California | Būdai ir kompozicijos, skirtos rnr molekulės nukreipiamai tikslinės dnr modifikacijai ir rnr molekulės nukreipiamam transkripcijos moduliavimui |
ES2812599T3 (es) * | 2012-08-29 | 2021-03-17 | Sangamo Therapeutics Inc | Procedimientos y composiciones para el tratamiento de una afección genética |
US20140085593A1 (en) | 2012-09-21 | 2014-03-27 | Shenzhen China Star Optoelectronics Technology Co., Ltd | Mixture for Liquid Crystal Medium and Liquid Crystal Display Using the Same |
PT3502240T (pt) | 2012-11-27 | 2021-08-11 | Childrens Medical Ct Corp | Elementos reguladores distais de bcl11a como alvo para a reindução de hemoglobina fetal |
PT2921557T (pt) | 2012-12-12 | 2016-10-19 | Massachusetts Inst Technology | Engenharia de sistemas, métodos e composições guia otimizadas para a manipulação de sequências |
CA2910489A1 (en) * | 2013-05-15 | 2014-11-20 | Sangamo Biosciences, Inc. | Methods and compositions for treatment of a genetic condition |
EP3417880A1 (en) | 2013-06-05 | 2018-12-26 | Duke University | Rna-guided gene editing and gene regulation |
EP3019595A4 (en) | 2013-07-09 | 2016-11-30 | THERAPEUTIC USES OF A GENERIC CHANGE WITH CRISPR / CAS SYSTEMS | |
HRP20211563T1 (hr) | 2013-07-11 | 2022-01-07 | Modernatx, Inc. | Pripravci koji sadrže sintetske polinukleotide koji kodiraju proteine srodne crispr-u i sintetske sgrna, te postupci njihove uporabe |
WO2015021426A1 (en) | 2013-08-09 | 2015-02-12 | Sage Labs, Inc. | A crispr/cas system-based novel fusion protein and its application in genome editing |
CA3109801C (en) | 2013-08-22 | 2024-01-09 | Andrew Cigan | Plant genome modification using guide rna/cas endonuclease systems and methods of use |
JP2015092462A (ja) | 2013-09-30 | 2015-05-14 | Tdk株式会社 | 正極及びそれを用いたリチウムイオン二次電池 |
WO2015113063A1 (en) | 2014-01-27 | 2015-07-30 | Georgia Tech Research Corporation | Methods and systems for identifying crispr/cas off-target sites |
WO2015141521A1 (ja) | 2014-03-21 | 2015-09-24 | 株式会社日立国際電気 | 基板処理装置、半導体装置の製造方法及び記録媒体 |
EP3122880B1 (en) | 2014-03-26 | 2021-05-05 | Editas Medicine, Inc. | Crispr/cas-related methods and compositions for treating sickle cell disease |
KR101886381B1 (ko) | 2014-05-28 | 2018-08-10 | 기초과학연구원 | 불활성화된 표적 특이적 뉴클레아제를 이용한 표적 dna의 분리 방법 |
JP6197169B2 (ja) | 2014-09-29 | 2017-09-20 | 東芝メモリ株式会社 | 半導体装置の製造方法 |
KR20240013283A (ko) | 2014-12-03 | 2024-01-30 | 애질런트 테크놀로지스, 인크. | 화학적 변형을 갖는 가이드 rna |
EP3262172A2 (en) | 2015-02-23 | 2018-01-03 | Crispr Therapeutics AG | Materials and methods for treatment of hemoglobinopathies |
US20180200387A1 (en) | 2015-02-23 | 2018-07-19 | Crispr Therapeutics Ag | Materials and methods for treatment of human genetic diseases including hemoglobinopathies |
EP3274454B1 (en) | 2015-03-25 | 2021-08-25 | Editas Medicine, Inc. | Crispr/cas-related methods, compositions and components |
JP6873911B2 (ja) | 2015-04-06 | 2021-05-19 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | 初代細胞において標的核酸の遺伝子調節を誘導するためにインビトロで行う方法 |
EP3313989A4 (en) | 2015-06-29 | 2018-12-05 | Ionis Pharmaceuticals, Inc. | Modified crispr rna and modified single crispr rna and uses thereof |
WO2017077394A2 (en) | 2015-11-04 | 2017-05-11 | Crispr Therapeutics Ag | Materials and methods for treatment of hemoglobinopathies |
JP2019500043A (ja) | 2015-12-28 | 2019-01-10 | ノバルティス アーゲー | 異常ヘモグロビン症の治療用組成物および方法 |
EP3430142A1 (en) | 2016-03-14 | 2019-01-23 | Editas Medicine, Inc. | Crispr/cas-related methods and compositions for treating beta hemoglobinopathies |
CN109715198B (zh) | 2016-04-18 | 2022-09-06 | 克里斯珀医疗股份公司 | 用于治疗血红蛋白病的材料和方法 |
WO2017191503A1 (en) | 2016-05-05 | 2017-11-09 | Crispr Therapeutics Ag | Materials and methods for treatment of hemoglobinopathies |
WO2018081476A2 (en) | 2016-10-27 | 2018-05-03 | Intima Bioscience, Inc. | Viral methods of t cell therapy |
MA50849A (fr) | 2017-10-26 | 2020-09-02 | Vertex Pharma | Substances et procédés pour le traitement d'hémoglobinopathies |
EP3749768A1 (en) | 2018-02-05 | 2020-12-16 | Vertex Pharmaceuticals Incorporated | Materials and methods for treatment of hemoglobinopathies |
-
2016
- 2016-02-23 EP EP16717452.3A patent/EP3262172A2/en active Pending
- 2016-02-23 CN CN201680022517.8A patent/CN107532168A/zh active Pending
- 2016-02-23 US US15/550,951 patent/US20180030438A1/en active Pending
- 2016-02-23 CA CA2977447A patent/CA2977447A1/en active Pending
- 2016-02-23 SG SG11201706767RA patent/SG11201706767RA/en unknown
- 2016-02-23 US US15/550,943 patent/US10738305B2/en active Active
- 2016-02-23 EP EP16717451.5A patent/EP3262171A2/en active Pending
- 2016-02-23 CN CN201680022404.8A patent/CN107532182A/zh active Pending
- 2016-02-23 WO PCT/IB2016/000276 patent/WO2016135557A2/en active Application Filing
- 2016-02-23 BR BR112017017812A patent/BR112017017812A2/pt not_active Application Discontinuation
- 2016-02-23 AU AU2016225178A patent/AU2016225178B2/en active Active
- 2016-02-23 WO PCT/IB2016/000282 patent/WO2016135558A2/en active Application Filing
- 2016-02-23 SG SG11201706766WA patent/SG11201706766WA/en unknown
- 2016-02-23 CA CA2977455A patent/CA2977455A1/en active Pending
- 2016-02-23 BR BR112017017810A patent/BR112017017810A2/pt not_active IP Right Cessation
- 2016-02-23 AU AU2016225179A patent/AU2016225179C1/en active Active
-
2020
- 2020-06-23 US US16/909,283 patent/US20210317450A9/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US20180030438A1 (en) | 2018-02-01 |
EP3262172A2 (en) | 2018-01-03 |
US10738305B2 (en) | 2020-08-11 |
AU2016225178B2 (en) | 2022-05-05 |
CA2977455A1 (en) | 2019-09-01 |
WO2016135557A3 (en) | 2016-10-20 |
US20210317450A9 (en) | 2021-10-14 |
WO2016135558A3 (en) | 2016-10-20 |
WO2016135558A2 (en) | 2016-09-01 |
AU2016225179A1 (en) | 2017-08-31 |
CN107532168A (zh) | 2018-01-02 |
US20210009998A1 (en) | 2021-01-14 |
CA2977447A1 (en) | 2016-09-01 |
AU2016225179B2 (en) | 2022-05-05 |
SG11201706767RA (en) | 2017-09-28 |
BR112017017810A2 (pt) | 2018-04-10 |
AU2016225178A1 (en) | 2017-08-31 |
CN107532182A (zh) | 2018-01-02 |
AU2016225178A9 (en) | 2022-05-05 |
EP3262171A2 (en) | 2018-01-03 |
WO2016135557A2 (en) | 2016-09-01 |
US20180021413A1 (en) | 2018-01-25 |
SG11201706766WA (en) | 2017-09-28 |
AU2016225179C1 (en) | 2022-11-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112017017812A2 (pt) | materiais e métodos para tratamento de hemoglobinopatias | |
WO2016135559A3 (en) | Materials and methods for treatment of human genetic diseases including hemoglobinopathies | |
WO2017077394A3 (en) | Materials and methods for treatment of hemoglobinopathies | |
MX2019002356A (es) | Compuestos de biarilo utiles como inmunomoduladores. | |
MX2018005829A (es) | Composiciones para tratar el cabello. | |
ECSP17028310A (es) | Composiciones y métodos para inhibir la expresión del gen HAO1 (hidroxiácido-oxidasa 1 (glicolato-oxidasa)) | |
GT201500294A (es) | Compuestos de biaril-amida como inhibidores de cinasa | |
DOP2014000233A (es) | Compuestos de microarn y métodos de modulación de la actividad de mir-21 | |
BR112018007538A2 (pt) | células exterminadoras naturais e células ilc3 e usos das mesmas | |
GT201400034A (es) | Compuestos y composiciones como inhibidores de la quinasa c-kit | |
SG10201809290SA (en) | Compositions and Methods to Treating Hemoglobinopathies | |
MX360050B (es) | Preparacion y composiciones de azufre con valencia cero, altamente bio-disponibles, y sus usos. | |
BR112016016539A2 (pt) | micro-organismos recombinantes enriquecidos com carboidratos | |
MX2016003486A (es) | Inhibidores de glucosilceramida sintasa para el tratamiento de enfermedades. | |
PH12018500379A1 (en) | Biopharmaceutical compositions | |
MX2022013454A (es) | Moduladores de la actividad del complemento. | |
MX2020011415A (es) | Metodos de usar zscan4 para rejuvenecer celulas humanas. | |
EA201791182A1 (ru) | Новые производные 2'- и/или 5'-аминокислотных эфиров фосфороамидатов 3'-дезоксиаденозина в качестве противораковых соединений | |
PH12018500690A1 (en) | Novel insulin analogs and use thereof | |
MX2021009554A (es) | Produccion de virus en cultivos celulares. | |
BR112017006552A2 (pt) | composições e métodos para inibir a atividade biológica de biomoléculas solúveis | |
PH12014502627B1 (en) | Anti-ageing composition containing dehydrogenated abietic acid as active ingredient | |
DOP2010000251A (es) | Paramyxovirus eficaz como antitumoral | |
BR112017020513A2 (pt) | método de produção de peixe para transplante, peixe para transplante, método de produção de espécie híbrida de peixe e espécie híbrida de peixe | |
BR112018008931A8 (pt) | ?compostos para tratamento de distúrbios hipoproliferativos? |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] |